Moderna, Inc. Revenues
Moderna, Inc. (MRNA) reported Revenues of $344.00 million for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-03.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2023-08-03
- Moderna, Inc. revenues for the quarter ending 2023-06-30 was $344.00M, a 92.76% decline year-over-year.
- Moderna, Inc. revenues for the quarter ending 2023-03-31 was $1.86B, a 69.30% decline year-over-year.
- Moderna, Inc. revenues for the quarter ending 2022-12-31 was $5.08B, a 29.50% decline year-over-year.
- Moderna, Inc. revenues for the quarter ending 2022-09-30 was $3.36B, a 32.30% decline year-over-year.
- Moderna, Inc. revenues for fiscal 2022 was $19.26B, a 4.29% increase from fiscal 2021.
- Moderna, Inc. revenues for fiscal 2021 was $18.47B, a 2200.25% increase from fiscal 2020.
- Moderna, Inc. revenues for fiscal 2020 was $803.00M, a 1238.33% increase from fiscal 2019.
- Moderna, Inc. revenues for fiscal 2019 was $60.00M, a 55.58% decline from fiscal 2018.
| Period end | Revenues 3 month | Revenues 3 month as first filed | Revenues 6 month | Revenues 6 month as first filed | Revenues 9 month | Revenues 9 month as first filed | Revenues 12 month | Revenues 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2023-06-30 | $344.00M 10-Q · filed 2023-08-03 | $2.21B 10-Q · filed 2023-08-03 | $7.29B derived: sum of 3 quarters · filed 2023-08-03 | $10.65B derived: sum of 4 quarters · filed 2023-08-03 | ||||
| 2023-03-31 | $1.86B 10-Q · filed 2023-05-04 | $6.95B derived: sum of 2 quarters · filed 2023-05-04 | $10.31B derived: sum of 3 quarters · filed 2023-05-04 | $15.06B derived: sum of 4 quarters · filed 2023-08-03 | ||||
| 2022-12-31 | $5.08B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $8.45B derived: sum of 2 quarters · filed 2023-02-24 | $13.20B derived: sum of 3 quarters · filed 2023-08-03 | $19.26B 10-K · filed 2023-02-24 | ||||
| 2022-09-30 | $3.36B 10-Q · filed 2022-11-03 | $8.11B derived: sum of 2 quarters · filed 2023-08-03 | $14.18B 10-Q · filed 2022-11-03 | $21.39B derived: sum of 4 quarters · filed 2023-08-03 | ||||
| 2022-06-30 | $4.75B 10-Q · filed 2023-08-03 | $10.81B 10-Q · filed 2023-08-03 | $18.03B derived: sum of 3 quarters · filed 2023-08-03 | $23.00B derived: sum of 4 quarters · filed 2023-08-03 | ||||
| 2022-03-31 | $6.07B 10-Q · filed 2023-05-04 | $13.28B derived: sum of 2 quarters · filed 2023-05-04 | $18.25B derived: sum of 3 quarters · filed 2023-05-04 | $22.60B derived: sum of 4 quarters · filed 2023-05-04 | ||||
| 2021-12-31 | $7.21B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $12.18B derived: sum of 2 quarters · filed 2023-02-24 | $16.53B derived: sum of 3 quarters · filed 2023-02-24 | $18.47B 10-K · filed 2023-02-24 | ||||
| 2021-09-30 | $4.97B 10-Q · filed 2022-11-03 | $9.32B derived: sum of 2 quarters · filed 2022-11-03 | $11.26B 10-Q · filed 2022-11-03 | $11.83B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-06-30 | $4.35B 10-Q · filed 2022-08-03 | $6.29B 10-Q · filed 2022-08-03 | $6.86B derived: sum of 3 quarters · filed 2023-02-24 | $7.02B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-03-31 | $1.94B 10-Q · filed 2022-05-04 | $2.51B derived: sum of 2 quarters · filed 2023-02-24 | $2.67B derived: sum of 3 quarters · filed 2023-02-24 | $2.73B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2020-12-31 | $571.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $728.00M derived: sum of 2 quarters · filed 2023-02-24 | $795.00M derived: sum of 3 quarters · filed 2023-02-24 | $803.00M 10-K · filed 2023-02-24 | $803.39M 10-K · filed 2021-02-26 | |||
| 2020-09-30 | $157.00M 10-Q · filed 2021-11-04 | $157.91M 10-Q · filed 2020-10-30 | $224.00M derived: sum of 2 quarters · filed 2021-11-04 | $232.00M 10-Q · filed 2021-11-04 | $232.65M 10-Q · filed 2020-10-30 | $246.06M derived: sum of 4 quarters · filed 2021-11-04 | ||
| 2020-06-30 | $67.00M 10-Q · filed 2021-08-05 | $66.35M 10-Q · filed 2020-08-06 | $75.00M 10-Q · filed 2021-08-05 | $74.74M 10-Q · filed 2020-08-06 | $89.06M derived: sum of 3 quarters · filed 2021-08-05 | $106.10M derived: sum of 4 quarters · filed 2021-08-05 | ||
| 2020-03-31 | $8.00M 10-Q · filed 2021-05-06 | $8.39M 10-Q · filed 2020-05-07 | $22.05M derived: sum of 2 quarters · filed 2021-05-06 | $39.10M derived: sum of 3 quarters · filed 2021-05-06 | $52.18M derived: sum of 4 quarters · filed 2021-05-06 | |||
| 2019-12-31 | $14.05M 10-K · filed 2020-02-27 | $31.10M derived: sum of 2 quarters · filed 2020-10-30 | $44.18M derived: sum of 3 quarters · filed 2020-10-30 | $60.00M 10-K · filed 2022-02-25 | $60.21M 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $17.05M 10-Q · filed 2020-10-30 | $30.13M derived: sum of 2 quarters · filed 2020-10-30 | $46.15M 10-Q · filed 2020-10-30 | $81.58M derived: sum of 4 quarters · filed 2020-10-30 | ||||
| 2019-06-30 | $13.08M 10-Q · filed 2020-08-06 | $29.11M 10-Q · filed 2020-08-06 | $64.53M derived: sum of 3 quarters · filed 2020-08-06 | $106.29M derived: sum of 4 quarters · filed 2020-08-06 | ||||
| 2019-03-31 | $16.02M 10-Q · filed 2020-05-07 | $51.45M derived: sum of 2 quarters · filed 2020-05-07 | $93.20M derived: sum of 3 quarters · filed 2020-05-07 | $122.05M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | $35.42M 10-K · filed 2020-02-27 | $77.18M derived: sum of 2 quarters · filed 2020-02-27 | $106.03M derived: sum of 3 quarters · filed 2020-02-27 | $135.07M 10-K · filed 2021-02-26 | ||||
| 2018-09-30 | $41.76M 10-K · filed 2020-02-27 | $70.61M derived: sum of 2 quarters · filed 2020-02-27 | $99.65M 10-Q · filed 2019-11-06 | $191.55M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-06-30 | $28.85M 10-K · filed 2020-02-27 | $57.89M 10-Q · filed 2019-08-08 | $149.79M derived: sum of 3 quarters · filed 2020-02-27 | $192.27M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-03-31 | $29.04M 10-K · filed 2020-02-27 | $120.94M derived: sum of 2 quarters · filed 2020-02-27 | $163.41M derived: sum of 3 quarters · filed 2020-02-27 | $204.54M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2017-12-31 | $91.90M 10-K · filed 2019-03-13 | $134.38M derived: sum of 2 quarters · filed 2019-03-13 | $175.50M derived: sum of 3 quarters · filed 2019-03-13 | $205.82M 10-K · filed 2020-02-27 | ||||
| 2017-09-30 | $42.47M 10-K · filed 2019-03-13 | $83.59M derived: sum of 2 quarters · filed 2019-03-13 | $113.92M derived: sum of 3 quarters · filed 2019-03-13 | |||||
| 2017-06-30 | $41.12M 10-K · filed 2019-03-13 | $71.45M derived: sum of 2 quarters · filed 2019-03-13 | ||||||
| 2017-03-31 | $30.33M 10-K · filed 2019-03-13 | |||||||
| 2016-12-31 | $108.40M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |